November 18, 2014
To assist in the search for therapies that might contribute to curing HIV infection, scientists are seeking to identify biomarkers that are associated with control of viral load after an antiretroviral therapy (ART) interruption. If reliable predictors of viral load control could be identified, the effect of candidate therapies on these biomarkers could be evaluated without necessarily having to ask clinical trial participants to undergo ART interruptions (which can pose risks to health). Two recent papers report that certain measurements of the HIV reservoir show statistically significant associations with viral load rebound, although the results are not entirely consistent.
The SPARTAC trial studied the effects of a 48-week course of ART in people with acute HIV infection. The primary results were reported in the New England Journal of Medicine last year. In a paper in the journal Elife, the trial investigators describe assessments of whether the amount of HIV DNA in blood samples at ART interruption was linked to the time it took for HIV viral load to rebound to detectable levels, or the trial's primary endpoints (CD4 T cell count less than 350 or restart of ART). The level of total HIV DNA was significantly correlated with time to a viral load above 400 copies; the higher the HIV DNA level, the quicker the time to rebound. Significant associations were also observed between HIV DNA levels and time to reach a CD4 T cell count of less than 350 or ART restart. However, when an assay with a lower viral load cut-off of 50 copies was used, HIV DNA levels were no longer significantly associated with time to rebound.
The second paper, by Jonathan Li and colleagues, is based on analyses of participants in a randomized, placebo-controlled therapeutic HIV vaccine trial involving Merck's Ad5-based vaccine candidate (since discontinued). The study design involved a 16-week analytical treatment interruption (ATI). The researchers were able to document statistically significant correlations between pre-ATI HIV RNA and DNA measurements and the viral load set point during the ATI. However, neither measure was significantly associated with time to viral load rebound above 200 copies.
As part of the preparation for this protocol, Jonathan Li has performed an analysis of six prior ACTG trials involving ATIs to gain an understanding of what proportion of individuals are able to maintain undetectable viral loads for an extended period. The results were presented at the IDSA conference last month, showing that overall 6% of 263 participants had levels below 200 copies at week 12 of an ATI. The phenomenon was more common among those treated during acute or recent HIV infection compared to chronically infected individuals. Galit Alter has collaborated with Li to look at possible correlates of control in these study participants, identifying the presence of specific antibody subclasses that are associated with enhanced natural killer cell activity (this preliminary work was presented at the NIAID Strategies for an HIV Cure meeting the week following the IDSA conference). The forthcoming ACTG MAP biomarker study should hopefully be able to build on these findings.
Richard Jefferys is the coordinator of the Michael Palm HIV Basic Science, Vaccines & Prevention Project Weblog at the Treatment Action Group (TAG). The original blog post may be viewed here.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.